PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Elliott Boulding sold 15,521 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $53.30, for a total value of $827,269.30. Following the completion of the sale, the vice president now directly owns 103,901 shares in the company, valued at approximately $5,537,923.30. The trade was a 13.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Mark Elliott Boulding also recently made the following trade(s):
- On Wednesday, February 19th, Mark Elliott Boulding sold 1,333 shares of PTC Therapeutics stock. The stock was sold at an average price of $50.10, for a total value of $66,783.30.
- On Tuesday, January 7th, Mark Elliott Boulding sold 1,543 shares of PTC Therapeutics stock. The stock was sold at an average price of $45.34, for a total value of $69,959.62.
PTC Therapeutics Price Performance
Shares of NASDAQ:PTCT opened at $54.50 on Friday. The company has a market cap of $4.30 billion, a P/E ratio of -9.18 and a beta of 0.66. PTC Therapeutics, Inc. has a 1 year low of $24.00 and a 1 year high of $55.65. The stock’s fifty day moving average price is $48.60 and its 200-day moving average price is $43.57.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Several brokerages recently weighed in on PTCT. Morgan Stanley reaffirmed an “overweight” rating and issued a $70.00 price target (up from $67.00) on shares of PTC Therapeutics in a research note on Friday, March 7th. JPMorgan Chase & Co. increased their target price on PTC Therapeutics from $72.00 to $78.00 and gave the stock an “overweight” rating in a research note on Friday. Bank of America raised PTC Therapeutics from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $41.00 to $55.00 in a research note on Tuesday, March 11th. Citigroup increased their target price on PTC Therapeutics from $32.00 to $45.00 and gave the stock a “sell” rating in a research note on Wednesday, February 12th. Finally, Wells Fargo & Company increased their target price on PTC Therapeutics from $56.00 to $68.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $64.00.
Get Our Latest Research Report on PTCT
About PTC Therapeutics
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Featured Stories
- Five stocks we like better than PTC Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Where to Find Earnings Call Transcripts
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What does consumer price index measure?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.